Literature DB >> 7254769

Midline forehead flap in reconstructive procedures of the eyelids and exenterated socket.

R K Dortzbach, M J Hawes.   

Abstract

The midline forehead flap is a good, versatile alternative when more standard techniques cannot be used to reconstruct the eyelids, medial canthus or exenterated socket. Indications are where: (1) the recipient site has a poor blood supply; (2) standard reconstructive procedures have failed; (3) deep, as well as superficial, tissue loss is present; and (4) extensive tissue loss is present. Four patients illustrate the value and versatility of the midline forehead flap. Disadvantages also are discussed.

Entities:  

Mesh:

Year:  1981        PMID: 7254769

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  6 in total

Review 1.  [Transposition flaps for reconstruction of deep defects of the medial eyelids. Fasciocutaneous rotations- and transposition flaps and modified pure fascial transposition flap].

Authors:  U Schaudig; T Grundmann; J Ussmüller
Journal:  Ophthalmologe       Date:  2004-05       Impact factor: 1.059

2.  Reconstruction of the eyelids after mohs surgery.

Authors:  Jamil Ahmad; David W Mathes; Kamel M Itani
Journal:  Semin Plast Surg       Date:  2008-11       Impact factor: 2.314

3.  Management of Naso-orbital Fistula following Maxillectomy: a Case Report.

Authors:  Rajaram Burrah; Ashok Shenoy; Vishal Rao; Purushotham Chavan; Thiagarajan Shivakumar
Journal:  Indian J Surg Oncol       Date:  2012-06-16

4.  Orbital exenteration: surgical and reconstructive strategies.

Authors:  C Mohr; J Esser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-05       Impact factor: 3.117

5.  Orbital exenteration: a 13 year Manchester experience.

Authors:  I Rahman; A E Cook; B Leatherbarrow
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  Reconstruction of orbital exenteration defects with bilobed forehead flap.

Authors:  Ayşe Dolar Bilge; Bulent Yazici; Fikret Kasapoglu
Journal:  Int Ophthalmol       Date:  2016-03-09       Impact factor: 2.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.